CDSCO panel Approves Sanofi's Protocol Amendment Proposal for to study Fitusiran
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved drug major Sanofi's protocol amendment proposal of Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia B, irrespective of inhibitor status.
However, this approval is subject to the condition that the firm has to submit the that interim analysis reports every 24 weeks of the proposed drug.
This came after the firm presented protocol amendment 03 version 1 dated 20.10.2023 and protocol amendment 04 version 1 dated 24.11.2023 protocol No. EFC1546.
Fitusiran is a monthly subcutaneous RNA interference therapy targeting antithrombin to increase thrombin generation and reduce bleeding in hemophilia with or without inhibitors.
The study medication, fitusiran, employs a unique mechanism of action—small interfering with RNA, or siRNA. The siRNA can be customized to block production of any protein, leading to lower levels of the target protein. In this case it blocks antithrombin, which inhibits a coagulation protein called thrombin.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.